Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ATP4A | P20648 | 2/20 | 0.34 |
| ▸ | ATP4B | P51164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775196 | 0.89 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1TDP1ATP4AATP4B | |
| SCHEMBL4777348 | 0.76 | GBA1 (0.36) | ALDH1A1L3MBTL1TDP1ATP4AATP4B | |
| SCHEMBL6218252 | 0.75 | HTT (0.38) | ALDH1A1L3MBTL1LMNAHTTKLKB1 | |
| SCHEMBL6713344 | 0.71 | CYP2C19 (0.42) | ALDH1A1TSHRLMNAHTTSMN1; SMN2 | |
| SCHEMBL4775733 | 0.71 | FES (0.35) | ALDH1A1ATP4AATP4BLMNAHTT | |
| SCHEMBL27634278 | 0.69 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1TDP1TSHRHTT | |
| SCHEMBL4765503 | 0.67 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1TDP1TSHRLMNA | |
| SCHEMBL26037955 | 0.65 | TSHR (0.52) | L3MBTL1ATP4AATP4BTSHRHTT | |
| SCHEMBL16828235 | 0.64 | ADORA2A (0.55) | ALDH1A1TSHRLMNAHTTPOLB | |
| SCHEMBL1066576 | 0.64 | TSHR (0.67) | ALDH1A1L3MBTL1TDP1TSHRNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513524-A4 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7220758-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060252792-A1 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-11-09 | — | — | US | disclosed |
| US-7125890-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1513524-A2 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20050032830-A1 | Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-10 | — | — | US | disclosed |
| US-6797718-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-28 | — | — | US | disclosed |
| US-20040010007-A1 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-15 | — | — | US | disclosed |
| WO-2003103584-A2 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252792-A1 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | IL2, IL4, MYD88 | ALDH1A1 1803/4885L3MBTL1 2072/4885TDP1 2306/4885 |
| US-20050032830-A1 | Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors | IL2, IFNG, TSLP | ALDH1A1 940/4885L3MBTL1 2518/4885TDP1 2716/4885 |
| US-20040010007-A1 | Ether substituted imidazopyridines | IL2, IL4, MYD88 | ALDH1A1 1803/4885L3MBTL1 2072/4885TDP1 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.